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This paper presents a review of the major anatomical,
biochemical and physiological effects of estrogens upon
the kidney. The field awaits a careful, systematic and
comprehensive study.
Evidence for estrogen receptors in the kidney
When "physiological" doses of tritiated estradiol are
administered to rats, the level of radioactivity in
"estrogen-unresponsive" tissues (kidney, liver, muscle)
reaches a maximum within 15 mm, then falls, parallel-
ing the blood concentration, to reach zero at about
16 hr [I]. In contrast, the incorporation of the labeled
hormone by "estrogen-responsive" tissues (uterus,
vagina) now known to contain specific estrogen recep-
tors follows a different pattern, the radioactivity
rising to a maximum at 60 to 90 mm while the blood
concentration is falling. At two hours, renal concentra-
tion of radioactivity is six or seven times that in blood
or muscle, about one-sixth that in uterus [1]. These
data permit no definite conclusions about the presence
or absence of renal estrogen receptors, but recent work
has demonstrated the formation of specific estradiol-
macromolecule complexes in the cytosol and nuclei of
fetal guinea pig kidney [2, 3]; these complexes appear
to be distinct from those formed by aldosterone. King
and Mainwaring have found low concentrations of
what appears to be a I 7-estradiol receptor in rat
kidney; it seems to be localized in the nuclear chroma-
tin [4]. Further studies will be needed to determine
whether these receptors are interstitial or tubular and
what their distribution is.
Morphological effects of estrogen on the kidney
Gonadectomy reduces kidney weight in male rats
but not in females [5]; testosterone elicits renal hyper-
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trophy, chiefly localized to the tubules, in normal and
ovariectomized female rats and castrated males. Estro-
gens appear to have an opposite effect: one study has
shown an increased growth rate of the kidney after
ovariectomy, and administration of large amounts of
estrogen reduces kidney weight and may produce cyst-
like degenerative changes in the juxtamedullary layer
of the cortex [5, 6]. Prolonged administration of estro-
gen to hamsters induces an insignificant increase in the
weight of the kidney [7] and gives rise to "estrogen-
dependent" renal tumors [4]. An absence of anabolic
effect of estrogen on the kidney of certain lower forms
has been demonstrated; whereas androgens stimulate
the development of the sexual segment of the kidney in
the Indian house lizard, estrogens have no such
action [8].
Under certain conditions, estrogens have been
shown to produce pathological changes in the renal
tubule. Pretreatment of rats with estrone enhances
renal tubular sensitivity to the hypoxic changes in-
duced by vasopressin administration [9] and clamping
of the renal pedicle [10]. Focal renal cortical necrosis
ensues, the major changes being in the epithelial cells
of the proximal convoluted tubule and Henle's loop.
Perhaps this is a valid experimental counterpart of the
bilateral renal cortical necrosis of late human preg-
nancy.
Very few data are available on estrogen-induced
changes in the minute anatomy of the kidney. After
short courses of estradiol administration, Rohr and
Bertram have observed more distinct electron micro-
scopic alterations in the straight portion of the rat
proximal tubule than in the convoluted portion [11].
Estrogen elicits both similar and opposite effects upon
the relative volumes of various cellular organelles in
the two segments, but, in general, the hormone tends
to minimize the morphologic differences betwcen the
two segments. On the basis of the estrogen-induced
changes in organelles, these inferences about tubular
Estrogens and the kidney 367
function have been drawn: there ensue inhibition of
reabsorptive processes in the proximal convoluted
tubule, reduction of protein synthesis in both seg-
ments, stimulation of secretory processes in the
straight portion and activation of intracellular anabol-
ism in both segments [11]. A single dose of estradiol
increases nuclear volume by 14% in the straight por-
tion of the proximal tubule; larger doses given for six
days induce an increased nuclear volume in the cells
of the proximal convoluted tubules also [12]. The
physiological significance of these findings awaits
further study.
Biochemical effects of estrogen on the kidney
Changes in the concentration and distribution of
several enzymes in the kidney can be elicited by estro-
gen. There is evidence that some of the demonstrated
increases in enzyme concentration are due to estrogen-
induced synthesis of new enzyme protein. As with the
morphologic changes brought about by estrogen (v.
supra), the functional significance of its actions on
renal enzymes is not yet clear.
In a study of basic mechanisms of protein synthesis
in the renal cortex of the rat, Trachewsky, Majumdar
and Congote observed that 1 7/3-estradiol decreases the
capacity of ribosomes to incorporate phenylalanine
into polyphenylalanine, an effect opposite to that
exerted by aldosterone and other mineralocorticoids
[13]. Estrogen administration alters the "profile" of
renal esterase isozymes in the hamster [7], brings about
a reduction in /3-hydroxybutyric dehydrogenase
activity in the distal portion of the proximal convoluted
tubule [14], inhibits renal NADH2-oxidase [15] and
lowers renal transamidinase activity in the rat [16].
In this species, kidney alkaline phosphatase con-
centration is increased by estrogen [17—21]. The hor-
mone accelerates attainment of the normal adult
distribution of enzyme in the kidney [19]. The major
increase in enzyme activity occurs in the straight or
distal portions of the proximal convoluted tubule [17,
18]. With massive amounts of estrogen there is also an
increase in acid phosphatase activity in the renal cor-
tex [17, 20]. The rise in alkaline phosphatase concentra-
tion appears to be related to increased protein synthe-
sis generally. Von Deimling et al have shown a close
relationship between the rise in alkaline phosphatase
concentration and estradiol-induced enhancement of
incorporation of 3H-cytidine into the nuclei and
nucleoli of the straight segment of the proximal
tubules [22]. Further, actinomycin prevents the
estradiol-dependent increase in renal alkaline phos-
phatase concentration [23]. In a study of the effects of
estrogens upon glucuronide synthesis, Himaya and
his co-workers found that large doses of estradiol or
diethylstilbestrol increased N-acetylglucosaminyltrans-
ferase activity in rabbit kidney, an action they postu-
lated to be due to stimulation of enzyme synthesis
together with an activation of the enzyme [24].
Glucose-6-phosphatase activity in the kidney also
rises in response to estradiol administration, more or
less in parallel with the sodium and potassium content
of renal tissue [25]. Sequential administration of
estradiol (or estriol) and progesterone to rats reduces
sodium concentration in the cortex and medulla, but
does not change it in the papilla; potassium concentra-
tion is increased in the cortex, unchanged in the
medulla and reduced in the papilla [26, 27].
Mechanism of action of estrogen. In "target"
tissues, e.g., uterus, estrogen raises the tissue content
of water, phospholipid and glycogen; these early effects
are followed by a rise in total RNA and protein
concentrations 6 to 12 hr after the hormone is adminis-
tered, with an increase in DNA occurring much later
[28]. It is now well established that estrogen exerts its
cellular effects by a two-step process: first, it binds to a
receptor protein in the cytosol; "the steroid-receptor
complex is [then] translocated to the nucleus, where it
associates with a specific acceptor site.. . and in some
way accelerates the rate of certain nuclear bio-
synthetic processes" [28]. In some species, all tissues
contain estrogen-binding protein, "target" tissues
(uterus) containing much more than "nontarget"
organs (e.g., kidney), a finding which suggests a
"quantitative rather than qualitative difference with
respect to [estrogen-] receptor protein" [28]. Further
studies are needed to determine exactly where adminis-
tered estrogen localizes in the kidney, the amount and
distribution of estrogen-receptor protein in the kidney
of higher mammals, and the role, if any, of that pro-
tein in mediating the action of estrogen upon renal
function.
Effects of estrogen on physiological functions of
the kidney
Early studies of renal function during human preg-
nancy, taken as a naturally occurring state of hyperes-
trinism, showed only minimal increases in renal blood
flow and glomerular filtration rate (GRF) [29]. The
prevalent view was that normal pregnancy "has no
effect on renal function" [29]. Later studies have
shown unequivocally that GFR increases up to 50%
during uncomplicated pregnancy with a parallel rise in
tubular reabsorptive capacity (e.g., for sodium) [30].
Of course it is now clear that, from the endocrine
point of view, pregnancy cannot be regarded simply as
a pure state of estrogen excess: the roles of grossly
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increased secretory rates of progesterone and aldo-
sterone have to be taken into account; among the
hormonal complexities of gestation, it is not possible
to determine what is the isolated action of the raised
secretory rate of estrogen on the kidney.
Attempts to assess the isolated effect of estrogen have
been imperfect, since almost all of them have been
done in intact animals, so that the possible enhancing
or blunting effects of endogenous estrogen, progester-
one and adrenocortical steroids cannot be excluded.
From the data available, one concludes that the effects
of estrogen upon renal hemodynamics are slight. In
the dog, bilateral ovariectomy does not affect GFR,
diodrast clearance or Tm for diodrast [31]; administra-
tion of estradiol to female dogs does not alter or
slightly lowers GFR and reduces tubular excretory
mass only after hormone administration has been
stopped [32]. Estradiol given to intact female dogs for
II to 14 days induces small rises in GFR, an effect not
observed in a single ovariectomized animal [33]. The
significance of this study is not easy to evaluate be-
cause the treated animals developed anemia and ab-
normalities in capillary fragility and the clotting
mechanism [33]. Short-term administration of stil-
bestrol to normal dogs raises renal plasma flow and, to
a lesser extent, GFR [34]. There is one good study of
the effect of 1 7fl-estradiol in adrenalectomized dogs:
Johnson et al have shown slight but not statistically
significant increases in creatinine and para-amino-
hippurate (PAH) clearances after administration of an
eight-day course of the hormone [35]. Since the dogs in
this study were maintained on deoxycorticosterone
acetate and cortisone or cortisone alone, an additive or
synergistic renal effect of estradiol together with the
adrenocortical steroid or steroids cannot be excluded,
but, as the authors correctly conclude, the estradiol
effect is certainly "independent of an action to in-
crease adrenal steroid secretion" [35].
In human subjects, estradiol benzoate or estradiol in
doses of 4 to 8 mg for periods of 3 to 12 days does not
change urine flow, GFR, renal plasma flow or tubular
reabsorption of glucose [36, 37]. Bilateral ovariectomy
also fails to affect these indices [38]. It is reasonable to
conclude from these results that the observed large
changes in GFR and tubular function of normal
human pregnancy cannot be ascribed to the effects of
estrogen.
An in vitro study has shown that estrogen diminishes
PAH uptake by rat kidney slices, especially in the
intact male; opposite actions are exerted by testoster-
one [5]. The authors infer a renotropic effect of andro-
gen and a renal-depressant action of estrogen in this
species; comparable sex differences in higher mammals
have not been demonstrated.
Effect of estrogen on sodium and water metabolism
Premenstrual edema and the edema of late preg-
nancy have traditionally suggested the idea that
estrogens might exert a sodium- and water-retaining
action, presumably operating through the kidney [39].
The work of the past four decades has shown that
some of this action is renal and some extrarenal.
Further, there are large differences in the response to
estrogen from species to species. Therefore, the data
are presented for greater clarity according to species:
rat, dog, ape, man.
In the rat, urine flow, urinary sodium concentration
and sodium excretion rate are lower at estrus (when
estrogen secretory rate is high) than at diestrus (estro-
gen low); urinary potassium concentration (but not
potassium excretion rate) is higher at estrus [40].
These observations suggest the possibility that adreno-
cortical production of mineralocorticoids might rise at
estrus, a hypothesis borne out by Hinsull and Crocker's
demonstration of increased secretory rates of aldo-
sterone and corticosterone during proestrus and
estrus [41]. The authors are careful to point out that
the increased mineralocorticoid activity and the reten-
tion of sodium and water at estrus are not a "pure"
estrogen effect, since progesterone secretion is also
high at the time of maximum estrogen secretion, i.e., at
estrus; the accepted view is that progesterone stimu-
lates aldosterone hypersecretion by opposing aldo-
sterone action upon the distal tubule with consequent
natriuresis, shrinkage of blood volume and aldo-
steronism. Estrogen is thought to exert its effects on
the adrenal cortex differently (v. infra) [41]. Radev has
found that estradiol or estriol given to female rats
before a course of progesterone inhibits this natriuretic
effect of the latter steroid and, in fact, promotes sodium
reabsorption [26, 27]. That estrogen also has the
capacity to influence extrarenal ionic and water
metabolism is suggested by Crocker who observed
increased water transfer by rat intestinal mucosa at
estrus and after administration of estradiol, and pre-
sented inferential evidence that the adrenal cortex and
the renin-angiotensin system might play a part [42].
There is also indirect evidence in other rodents that
estrogens may induce changes in electrolyte metabol-
ism and excretion via stimulation of adrenocortical
secretion of aldosterone. Stilbestrol raises urinary
potassium excretion in the guineapig [43] and adminis-
tration of estrogen to hamstersproduces morphological
lesions resembling those of aldosteronism [44].
In the dog, the demonstration that pregnancy pro-
longs the survival of adrenalectomized animals
naturally raised the possibility that the increased
secretion of female sex hormones might bring about
sufficient sodium retention to counter the natriuresis
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resulting from the lack of adrenocortical steroids [45].
Testing this hypothesis, Thorn and Engel observed
that marked water, sodium and chloride retention
occurs in intact male dogs given single injections of
estradiol, estrone or crude preparations of estrogen;
the crude estrogen has weak sodium- and chloride-
retaining effects in adrenalectomized animals, pro-
gesterone being less effective [46]. Neither estrogen nor
progesterone was definitely effective in prolonging the
survival of adrenalectomized dogs, but the modest
inhibition of natriuresis in these animals indicates that
"the effect of the sex hormones on the renal excretion
of electrolytes [is] not necessarily mediated through
the suprarenal gland" [46]. Further studies in dogs on
the mechanism of estrogen-induced sodium retention
have yielded no definite consensus. Richardson and
Houck show a fall in GFR in some intact dogs treated
with estradiol [32]; since the fractions of filtered
sodium and chloride remain constant with changing
GFR, the estrogen-induced retention of these ions (the
degree of which is not clear in this paper) is assumed to
be due to "a diminished load presented to the tubules
for reabsorption rather than to an enhanced absolute
tubular reabsorption" [32]. Dance, Lloyd and Pickford
describe a reduction in sodium and water excretion
during induced diuresis after stilbestrol administra-
tion; in these experiments stilbestrol raised GFR and
renal plasma flow (RPF), but the changes in electrolyte
excretion sometimes preceded those in clearance [34].
The authors suppose from their own and earlier work
that estrogen-induced retention of water and sodium
is independent of GFR and RPF and of the presence
of adrenals or gonads, and raise the possibility that
some of the stilbestrol effect on the kidney is indirect,
e.g., through an increase in water content of the tissues
generally [34, 47]. Careful work by Johnson et al has
demonstrated that estradiol and estriol are equally
potent in producing renal sodium retention in intact
dogs, without affecting potassium excretion; proges-
terone has little or no effect on sodium balance [48].
Since estradiol opposes the natriuresis of adrenalec-
tomized dogs maintained on constant amounts of
desoxycorticosterone acetate (DOCA) and cortisone
or cortisone alone, the inference is that the sodium-
retaining effect cannot be mediated through an estro-
gen-induced rise in adrenocortical secretion of aldo-
sterone [35, 46]. Johnson et al suggest several other
possible mechanisms [48]. A fall in GFR with a conse-
quent fall in the filtered load of sodium is ruled out by
the finding of a slight but not significant rise in GFR
during estradiol treatment [35]. Not excluded, inter
a/ia, is a direct action of estrogens on the renal tubule
at receptor sites the same as or different from those for
aldosterone [35, 48].
In the ape, the water-retaining action of estrogens
appears to be at least partly exerted at extrarenal sites.
Administration of estrogens to rhesus monkeys pro-
duces retention of water and gain in weight, the re-
tained water being accommodated in the edematous
sexual skin [49]. The inference is that the hormone
causes a local increase of capillary permeability [49].
In man, sex hormones have long been implicated in
the edema of mid-cycle, the premenstrual phase of the
cycle [39] and the third trimester of pregnancy [30];
estrogens are suspect due to some of the animal data
already cited and to the familiar edema-inducing
property of estrogens given in large doses, as for treat-
ment of prostatic cancer (v. infra). Studies done in the
1920's and 1930's had disclosed that there is general-
ized edema and impaired excretion of water at the
time of menstruation [39], and that in pregnancy and
the puerperium, sodium is retained during periods of
high estrogen concentration and is lost at times when
estrogen values are falling [50]. The importance of
estrogens in these natural edematous states seemed
diminished by several observations: the now-recog-
nized aldosteronism of the luteal phase of the men-
strual cycle [51] and of late pregnancy [30]; the fact
that as much edema, weight gain and sodium and
water retention occur before menstruation, when estro-
gen and progesterone concentrations are low, as are
found at mid-cycle when estrogen secretion is high
[39]; and one early study which failed to show a
diminution of urine volume during the administration
of estradiol benzoate to normal, postmenopausal or
ovariectomized women [52]. More recent work has
indicated that estrogens exert a moderate sodium-
retaining effect in man. Dignam, Voskian and Assali
demonstrated in ovariectomized or postmenopausal
women that estradiol (8 mg daily for three to six days)
reduces the renal excretion of sodium and water with-
out much effect on potassium balance or body weight
[37]. In a detailed (and often misquoted) study, Preedy
and Aitken observed in 11 normal subjects that seven-
day courses of estradiol benzoate (10 mg/day) produce
no sustained effect on weight or on the urinary output
of water, sodium or chloride, but rather a slight and
transient fall in water, sodium and chloride excretion;
potassium excretion is not affected; plasma volume and
probably extracellular fluid volume are increased [53].
Further studies in patients with hepatic, cardiac or
renal disease showed that estradiol causes sustained
retention of NaCI and water only in subjects with
impaired hepatic circulation [54, 55]; renal disease
(nephrotic syndrome) plays no primary role [55].
Johnson et al have summarized several further studies
in which large amounts of estriol and large or small
amounts of estradiol are usually but not invariably
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shown to decrease the renal excretion of sodium [48].
As for the mechanism by which estrogen induces
sodium retention in man, there is evidence both for
and against estrogen-stimulated aldosteronism [see
citations in reference 48]. Layne et al demonstrated
that estrogens (and estrogen-progestogen combina-
tions) alter the metabolism and plasma protein binding
of aldosterone and also raise its secretory rate 1.5- to
3-fold [56]; Crane and Harris report a 2.5-fold in-
crease in aldosterone excretion rate (AER) within the
first week of administering ethinyl estradiol, 0.5 mg/
day, the value for AER falling somewhat by the third
week when all but two of 14 subjects still show an in-
crease over the control value, but with only one-half
of those AER values being above the upper limit of
normal [57]. Evidence against a role for estrogen-
induced aldosteronism has been direct and indirect.
The principal direct evidence is that of Laidlaw, Ruse
and Gornall, who found that long-term administra-
tion of diethyistilbestrol (DES) produces no rise in
AER and that short-term administration of ethinyl
estradiol raises AER but not to levels above the normal
range [58]. Indirect, i.e., physiologic evidence is that
of Thorn and Engel, who observed that estradiol
appeared to produce a short delay in the natriuresis
that would be expected to follow the withdrawal of
adrenal cortical extract in a patient with Addison's
disease; the demonstration is not convincing in the
absence of a control study and because one cannot
exclude a residual sodium-retaining action of the
suprarenal extract [46]. Better indirect evidence is the
observation of several investigators that estrogen-
induced sodium retention is not accompanied by a
raised urinary excretion of potassium [37, 48, 53—55];
if significant aldosteronism were present, kaliuresis
should be found.
A reasonable conclusion seems to be that "the
sodium-retaining effect of estrogens cannot be
explained entirely on the basis of increased mineralo-
corticoid secretion" [48]. Data from this laboratory
support that conclusion and support an extraadrenal
mechanism of estrogen-induced fluid retention [59].
Diet hyistilbestrol (DES)-induced edema without
aldosteronism. Four castrated elderly males with
prostatic carcinoma but without evidence of cardiac,
renal or hepatic dysfunction were maintained on diets
constant in calories and in sodium, potassium and
chloride content. Following a control period of 12 to 15
days each patient received DES at a dosage level of 5,
20 or 500 mg/day. Cardiac, hepatic and renal function
was reassessed during estrogen administration. Body
weight, urine volume and urinary excretion of sodium,
potassium and chloride were measured daily. Plasma
concentrations of 1 7-hydroxycorticosteroids and 24-hr
urinary steroid excretion were quantified frequently by
the Silber-Porter and Norymberski techniques. In two
patients, blood volume determinations were carried
out before and during control and experimental
periods.
Aldosterone production was assessed in all cases, in
two patients by measuring 24-hr urinary excretion, and
in the other two subjects by determining aldosterone
secretory rate. Aldosterone excretion was determined
by the bio-assay method of Laragh and Stoerk [60],
secretory rate of aldosterone by the isotope dilution
procedure of Ulick, Laragh and Lieberman [61].
Three of the four patients became edematous during
estrogen treatment, two with gains in weight of 2 to 5
kg. Data from a single individual (patient 3) illustrate
characteristic findings. Weight gain of 3 kg occurred
after one week of daily administration of 500 mg of
DES. On day 8 of treatment, there was a transient drop
in urine volume from 2.0 to 1.1 liters/day, and at this
time ankle edema appeared. The patient continued to
gain weight (total, 5 kg) and edema persisted although
daily urine volume returned to the previous values. In
the face of these changes, the excretion of aldosterone,
measured by bioassay, did not rise but remained well
within the normal limits of 0 to 8 jzg/day [60]. Data
concerning urinary excretion of sodium, chloride and
potassium are not available in this patient, but in the
two other edematous subjects, there was no appreci-
able fall in urinary sodium excretion during the first 24
days of estrogen treatment.
It is noteworthy that the one patient who showed
neither edema nor weight gain was given a diet con-
taining only 500 mg of sodium per day (22 mEq). In
contrast, the three who became edematous received
normal sodium intakes of 3000 mg (130 mEq) daily.
Table 1 shows an increase in plasma volume during
estrogen administration, as measured by T-1824 dye
dilution, in the two patients so studied. Table 2 docu-
ments the expected rise in plasma 17-hydroxycortico-
steroids [62]. Control values were 9 to 27 g/100 ml of
plasma and rose to 37 to 92 tg/100 ml. On the other
hand, DES therapy did not greatly alter urinary
steroid excretion [63]. Table 3 shows urinary 17-keto-
Table 1. Expansion of plasma volume during admini-
stration of diethyistilbestrol (DES)
Patient No, Plasma volume, ml
Control DES, 500 mg/day
1 2037 2336
2 2506 2959—3070
Determined by Evans blue technique.
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Table 2. Rise in plasma cortisol values during admini-
stration of diethylstilbestrol (DES)
Table 5. Excretion or secretion of aldosterone during administra-
tion of diethylstilbestrol (DES)
Patient No. Plasma 17—OH—CS, g/100 ml
Control DES, 500 mg/day
3 23 37—61
4 24 53—60
1 11—27 76—85
2 9 55—92
Table 3. Urinary excretion of corticosteroids during administra-
tion of diethyistilbestrol (DES)
Patient No. Urinary steroid excretion, mg/day
Control DES, 500 mg/day
17-KS 17-OHCS 17-KS 17-OHCS
3
4
1
2
5—7 6
0—4 4—7
8—12
5—9 —
1—4 1—10
0—2 5—7
5—7 —
4—6 —
steroid and 1 7-hydroxycorticosteroid determinations
expressed in mg/24 hr. During estrogen administration
17-ketosteroid concentrations remained constant or fell
slightly. There was no appreciable change in urinary
1 7-hydroxycorticosteroids. Urinary 1 7-ketogenic ster-
oids were also unchanged (Table 4). Chromatographic
analysis and Silber-Porter quantification of the major
metabolites of cortisol (compound F), indicated in the
table as the sum of cortisol (F), tetrahydrocortisol
(THF) and tetrahydrocortisone (THE), failed to show
a significant change [63]. Table 5 summarizes aldo-
sterone production. Normal values for aldosterone
excretion are 0 to 8 pg/day [60]; for secretory rate, 80
to 200 g/day [61]. The control values are seen to be
within normal limits in each instance. In no case did
aldosterone excretion rise significantly during DES
administration whether there was edema or not.
Patient 1 in a later study carried out when he was re-
Table 4. Excretion of isolated urinary cortisol metabolites
during administration of diethylstilbestrol (DES)
Patient
No.
Urinary steroid excretion, mg/day
Control DES, 500 mg/day
17-KGS F+THF+
THE
17-KGS F+THF+
THE
1
2
8—15 4—8
6—15 3
8 6
10 3
Patient No. Aldosterone production, pg/day
Excretion 3 1.0—4.5 0.0
4 0.2 1.3
Secretion 1
2
5
200
161
—
181
100
144
115
ceiving 5 mg of DES daily and a more liberal sodium
intake, showed an aldosterone secretory rate of 58 1g/
day despite the presence of edema and 5-kg weight
gain.
The mechanism by which estrogen brings about
edema is still not entirely clear. Induced hypercortisol-
ism seems unlikely since in several species including
man, estrogen administration is accompanied by a fall
rather than a rise in excretion and secretion of cortico-
steroids [63], despite a rise in plasma cortisol [62]
mediated by a gross increase in plasma cortisol-binding
globulin. With regard to estrogenic influence upon
mineralocorticoid, the data of the present and some
earlier studies [58, 63] indicate little if any increase in
aldosterone production.
As an explanation of estrogen-induced edema, a
case can be made for an extraadrenal mechanism.
Furthermore, the fact that this edema occurs with
neither marked nor sustained effect on sodium and
water balance [53] suggests that there is an important
extrarenal mechanism as well.
In conclusion, the present data show that DES-
induced edema in man is not mediated by the adrenal
cortex.
Comment. It appears that estrogen is a much weaker
sodium-retaining hormone than aldosterone. The
sodium retention induced by estrogen is not related to
the "estrogenic" effect of the steroid: estradiol and
estriol are about equal in sodium-retaining potency
although estradiol is much the stronger estrogen [48].
The sodium retention induced by estrogen is not
accompanied by increased potassium excretion; the
renal mechanisms by which estrogen and aldosterone
variously inhibit urinary loss of NaC1 must therefore
differ. Although estrogen has the capacity to raise
aldosterone secretion, there is much evidence to indi-
cate that extraadrenal mechanisms are more important
in the production of salt retention and probably also of
edema. Since the effects of estrogens upon the conven-
tional indices of renal function are minimal, extrarenal
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mechanisms need to be taken into account. More care-
ful study is needed of a possible unique action of
estrogens upon the renal tubule, and further atten-
tion should be focussed on extrarenal factors, e.g.,
estrogen-induced changes in capillary permeability,
for which there is already some suggestive evidence in
apes [49] and in man [references cited in 39].
Prolactin, estrogens and fluid retention. The possi-
bility that estrogen-induced retention of fluid and
electrolytes may be mediated by prolactin is worthy of
consideration. In addition to significant extrarenal
effects on salt and water transport in the rat, prolactin-
induced renal retention of water, sodium and potas-
sium has been demonstrated in the conscious intact
rat and in perfused cat kidney [64—66]. In man the
intramuscular administration of ovine prolactin in
amounts calculated to produce physiologic blood
concentrations of the hormone results in a prompt and
sustained fall in urinary excretion of sodium and water
[671. The reported responsiveness of human blood
concentrations of endogenous prolactin to osmotic
stimuli [68, 69] further suggests an osmoregulatory role
for prolactin in man. Various data suggest an enhance-
ment of prolactin secretion by estrogen in the human
subject. Women show a greater rise in serum prolactin
concentration than men during surgical stress [70] and
after administration of TRH [71] or phenothiazine [72].
Estrogen treatment results in increased basal concentra-
tions of serum prolactin in some men [73] and enhances
the response of serum prolactin concentrations to
phenothiazine administration in both men and women
[72].
In summary, "although estrogen ... has not been
clearly shown to affect [physiologic] prolactin secre-
tion in man" [72], and prolactin itself "has received
little attention . . . [as to its possible] importance in the
regulation of fluid and electrolyte balance [in man]"
[67], further study of the interaction of these hormones
in regard to osmoregulation in man may shed light on
the complexities of various edematous states, particu-
larly those related to end-stage liver disease [74] and to
pregnancy and the menstrual cycle, in all of which
estrogens may contribute to the retention of sodium.
Effect of estrogen on the renin-angiotensin-
aldosterone system
Hypertension occasionally occurs in women receiv-
ing estrogen-progesterone combinations for contra-
ception [75], diethylstilbestrol (but not progesterone)
raises the concentration of plasma renin substrate
(PRS) in rat plasma [76] and estrogens increase the
production rate of aldosterone [56—58]. Together,
these findings have served to provoke intense interest
in the actions of sex hormones upon the mechanisms
controlling blood pressure, particularly the renin-
angiotensin-aldosterone system. In parallel with the
modest rise of aldosterone secretion during the luteal
phase of the human menstrual cycle, there is a slight
increase in plasma renin [77]; plasma renin and PRS
are raised, in a manner not closely related to the rise in
aldosterone secretion, during human pregnancy [78]
(but PRS is lowered in pregnant rats [79]); and several
reports from 1967 to the present have provided abun-
dant evidence that oral contraceptives usually raise
plasma renin activity (PRA) and PRS, and some-
times increase aldosterone excretion rate (AER) [56,
58].
The first question to be answered is whether estro-
gen or progesterone is the stimulating hormone. The
early report of Helmer and Griffith indicated that
estrogen is and progesterone is not [76]. Crane et al
found that ethinyl estradiol alone raises PRA in
women; the doses given were larger (0.5 mg/day) than
those in oral antiovulatory agents [80]. With a similar
dose of ethinyl estradiol, these workers again observed
a rise of PRA in normal men and women, but no rise
during administration of the progestational steroid,
medroxyprogesterone acetate [81]; they concluded that
the estrogenic, not the progestational component, of
contraceptive medications is the inciting agent for the
increase in PRA [82]. Weir et at made similar observa-
tions and reached the same conclusion, using PRS as
their index [83].
However, there are data leading to a different
inference. First, it is reasonable to suppose that pro-
gesterone may have the capacity to augment PRA:
this steroid is known to produce natriuresis by oppos-
ing directly the action of aldosterone on the renal
tubule [84]. The consequent shrinkage of blood vol-
ume stimulates aldosterone secretion, probably by
activation of the renin-angiotensin system. Second,
patients with luteal failure, i.e., women lacking the
normal rise of plasma progesterone concentration in
the second one-half of the menstrual cycle, fail to
show the expected luteal rise in PRA [77] and AER
[51, 85]. The authors draw what appears to be the
obvious conclusion that the rise of PRA in the luteal
phase is mediated by progesterone, not estrogen [85].
Nevertheless, it is fairly certain that conjugated estro-
gens, without added progesterone, have the capacity to
raise PRA, PRS and AER, and apparently to induce
hypertension [86]. The matter requires more detailed
study with strict attention to relative amounts of
steroid administered, and to the quantitative aspects
of dose-response.
The second question concerns the mechanism by
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which estrogen stimulates the renal pressor system.
The intimate mode of action of the steroid is not yet
understood; for example, there are no data on estro-
gen-induced morphologic changes in the juxtaglomeru-
tar apparatus, and it is difficult to trace the time
sequence of the induced abnormalities. There is a
reasonable degree of unanimity about what happens
to the renal pressor system when estrogen is adminis-
tered: PRS (angiotensinogen, hypertensinogen) rises,
PRA rises and the reaction velocity of renin with
endogenous PRS [87, 88] increases, renal and plasma
renin concentrations (PRC) fall, and aldosterone pro-
duction rate may or may not increase [75, 80—83, 86,
88—91]. The standard hypothesis concerning the
estrogen-induced rise of FRS is that the hormone
stimulates the hepatic biosynthesis of the substrate,
much as it stimulates the hepatic biosynthesis of
corticosteroid-binding globulin, ceruloplasmin, cer-
tain of the coagulation factors and other proteins
[83]. Estrogen also inhibits the hepatic synthesis of
other proteins; hence, Laragh et al have suggested that
the elevation in PRS could be due to a primary
deleterious effect of estrogen on the kidney in which
PRS would rise because there is not enough renin to
degrade it, as may be the case in renal insufficiency or
nephrectomy, conditions often associated with sharp
rises in PRS [75]. The rise in PRA appears to be related
both to an absolute increase in PRS [75, 88—91] and to
an accelerated rate of angiotensin formation from the
substrate [75, 87, 88]; chemical changes in the sub-
strate molecule are possible [75], and activators or
inhibitors of the renin-substrate reaction have not
been excluded [75, 87]. The increase of PRA in the
luteal phase of the menstrual cycle is accompanied by a
rise in PRC [89], but exogenous estrogen and estrogen-
progestogen combinations almost always suppress PRC
[83, 89—91]. There are atleasttwopossibleexplanations
for the fall in PRC: higher angiotensin concentrations,
owing either to increased PRS or to a faster rate of
angiotensin generation, or both, might exert a direct
inhibitory effect on release of renin from the kidney
[89, 91]; or "indirect suppression might result from
expanded extracellular volume and decreased renal
neurogenic tone" [89, 92]. In either case, the estrogen-
induced fall in PRC appears to be an element of the
feedback inhibition control of the renal pressor sys-
tem, in which a raised plasma concentration of angio-
tensin either directly or indirectly inhibits the renal
synthesis or release of renin. It is possible that those
few women treated with estrogen-progestogen com-
binations who develop hypertension fail, for some
reason, to reduce the renal production of renin in
response to usual inhibitory conditions, viz., increased
PRA, PRS, angiotensin, or volume expansion, or any
combination of these [75, 90, 91, 93].' Further com-
plications in interpreting the effects of estrogen on the
renin-angiotensin system are 1) in rabbits, estradiol
raises the uterine concentration of renin but does not
alter renal content of the enzyme [94], and 2) in rats,
there appears to be a dissociation between the strictly
estrogenic (e.g., uterotrophic) effects of the hormone
and its capacity to raise PRA [95].
More studies are needed, with particular emphasis
upon the effects of estrogen on all elements of the
renal pressor system: PRA, PRS, PRC and aldo-
sterone. One fact seems to be certain: estrogen does
not stimulate synthesis and release of renin by the
kidney.
Effects of the kidney on estrogens
Unaltered estrogen is excreted in the urine in very
small quantities; after administration of radio-
actively labeled estrone or estradiol, less than 4% of
the hormone appears in the urine in the unconjugated
form [96]. Only l0% of estradiol filtered at the
glomerulus is excreted; the urinary free estradiol
throughout the human menstrual cycle (22 to 341 ng/
day) correlates closely with the plasma estradiol
concentration, and is not influenced by the plasma
concentration of testosterone-estradiol-binding globu-
lin [97]. As for the conjugated estrogens, a much
larger quantity of estrogen glucuronide (glucurono-
side, glucosiduronate) than of estrogen sulfate appears
in the urine [96, 98]. There appears to be a close
correlation between the excretion rate of total estrogen
and creatinine clearance, and, therefore, probably
GFR [99], but a more important mechanism for
excretion of estrogen conjugates seems to be tubular
secretion. There is good evidence that estradiol
glucuronide is secreted by the renal tubules [98, 100,
101]; its rate of excretion has been shown to exceed
GFR in several studies. The free and sulfurylated
forms appear to be reabsorbed "with some leakage"
while the glucuronides are actively secreted [98]. The
conventional view is that most of the conjugation of
steroid hormones occurs in the liver, but it is now clear
that the kidney has the capacity to form estriol glu-
curonides in vitro and in vivo [102, 103], and probably
also the glycosides of estradiol and estrone [102, 103].
There are quantitative data concerning the renal dis-
position of the four major conjugates of estriol. Renal
clearances are as follows: estriol-3-sulfate, 15 to 87
ml/min; estriol-16-glucuronide, 195 to 410 mi/mm;
1 There is no ready explanation why most women receiving con-
traceptive medication, and who envince the same abnormalities
in the biochemical indices of the renal pressor system as do those
who develop hypertension, remain normotensive [75, 90, 91, 93.
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estriol-3-glucuronide, 70 to 170 mI/mm; and estriol-3-
sulfate-16-glucuronide, 22 to 43 mi/mm [104].
Most of the studies cited have been done in preg-
nant women; in the case of the earlier work, this was
because methods were lacking for the measurement of
estrogens, particularly plasma estrogens, in the non-
pregnant state. The data available concerning renal
clearance of estrogens [98—100, 104] have to be accepted
with the reservations imposed by the changes in renal
function that are characteristic of pregnancy [30]. Now
that more sensitive methods are at hand, one may
anticipate useful studies of the renal clearance, re-
absorption and tubular excretion of several estrogens.
With the use of such techniques, it may also be pos-
sible to discover what relationships exist between the
renal metabolism of estrogens and the intimate mode
of action of these steroids upon many biochemical
and physiological aspects of renal function.
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